EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)

被引：0

作者：

Helliwell, P. ^{[1
]}

Van den Bosch, F. ^{[2
]}

Coates, L. C. ^{[3
]}

Gladman, D. D. ^{[4
]}

Tasset, C. ^{[5
]}

Meuleners, L. ^{[5
]}

Gilles, L. ^{[6
]}

Gheyle, L. ^{[5
]}

Trivedi, M. ^{[7
]}

Alani, M. ^{[7
,8
]}

Besuyen, R. ^{[9
]}

Mease, P. J. ^{[8
,10
]}

机构：

[1] Univ Leeds, Leeds, W Yorkshire, England

[2] Ghent Univ Hosp, Ghent, Belgium

[3] Univ Oxford, Botnar Res Ctr, Oxford, England

[4] Univ Toronto, Toronto, ON, Canada

[5] Galapagos NV, Mechelen, Belgium

[6] LACO, Galapagos NV, Mechelen, Belgium

[7] Gilead Sci Inc, Foster City, CA USA

[8] Univ Washington, Seattle, WA 98195 USA

[9] Galapagos BV, Leiden, Netherlands

[10] Swedish Med Ctr, Seattle, WA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷

关键词：

D O I：

10.1136/annrheumdis-2020-eular.2495

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FRI0343

引用

页码：761 / 762

页数：2

共 50 条

[1] Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Mease, Philip
Coates, Laura C.
Helliwell, Philip S.
Stanislavchuk, Mykola
Rychlewska-Hanczewska, Anna
Dudek, Anna
Abi-Saab, Walid
Tasset, Chantal
Meuleners, Luc
Harrison, Pille
Besuyen, Robin
Van der Aa, Annegret
Mozaffarian, Neelufar
Greer, Joy M.
Kunder, Rebecca
Van den Bosch, Filip
Gladman, Dafna D.
[J]. LANCET, 2018, 392 (10162): : 2367 - 2377
[2] Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
van der Heijde, Desiree
Baraliakos, Xenofon
Gensler, Lianne S.
Maksymowych, Walter P.
Tseluyko, Vira
Nadashkevich, Oleg
Abi-Saab, Walid
Tasset, Chantal
Meuleners, Luc
Besuyen, Robin
Hendrikx, Thijs
Mozaffarian, Neelufar
Liu, Ke
Greer, Joy M.
Deodhar, Atul
Landewe, Robert
[J]. LANCET, 2018, 392 (10162): : 2378 - 2387
[3] EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Mease, P. J.
Deodhar, A.
Van der Heijde, D.
Behrens, F.
Kivitz, A.
Kim, J.
Singhal, S.
Nowak, M.
Banerjee, S.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 314 - 315
[4] Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo-Controlled, Phase 3 Trial
Mease, Philip J.
Hall, Stephen
FitzGerald, Oliver
van der Heijde, Desiree
Merola, Joseph F.
Avila-Zapata, Francisco
Cieslak, Dorata
Graham, Daniela
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
Kanik, Keith
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[5] Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial
Mease, Philip
Helliwell, Philip S.
Silwinska-Stanczyk, Paula
Miakisz, Malgorzata
Ostor, Andrew
Peeva, Elena
Vincent, Michael
Sikirica, Vanja
Winnette, Randall
Qiu, Ruolun
Li, Gang
Feng, Gang
Beebe, Jean
Martin, David
[J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1009 - 1011
[6] EFFICACY OF FILGOTINIB VS PLACEBO IN ACTIVE PSORIATIC ARTHRITIS: PATIENT-LEVEL DATA FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
Mease, Philip J.
Gladman, Dafna D.
van den Bosch, Filip
Stanislavchuk, Mykola
Rychlewska-Hanczewska, Anna
Tasset, Chantal
Meuleners, Luc
Besuyen, Robin
Gao, Jingjing
Trivedi, Mona
Coates, Laura C.
Helliwell, Philip
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 128 - 128
[7] EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Mease, P. J.
Deodhar, A.
Van der Heijde, D.
Behrens, F.
Kivitz, A.
Lehman, T.
Wei, L.
Nys, M.
Banerjee, S.
Nowak, M.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 137 - 138
[8] Filgotinib, an Oral, Selective Janus Kinase 1 Inhibitor, Is Effective in Psoriatic Arthritis Patients with an Inadequate Response to Conventional Disease-Modifying Anti-Rheumatic Drugs: Results from a Randomized, Placebo-Controlled, Phase 2 Study
Mease, Philip J.
Gladman, Dafna D.
van den Bosch, Filip
Rychlewska-Hanczewska, Anna
Dudek, Anna
Tasset, Chantal
Meuleners, Luc
Harrison, Pille
Besuyen, Robin
Kunders, Rebecca
Mozaffarian, Neelufar
Coates, Laura C.
Helliwell, Philip
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
[9] A phase 2 randomized controlled trial of the Janus Kinase (JAK) inhibitor filgotinib in patients with noninfectious uveitis
Srivastava, Sunil K.
Watkins, Tim
Quan Dong Nguyen
Sharma, Sumit
Scales, David
Dacey, Mark
Shah, Rajiv E.
Chu, David
Grewal, Dilraj S.
Faia, Lisa
Suhler, Eric B.
Genovese, Mark
Guo, Ying
Barchuk, William
Dick, Andrew D.
Rosenbaum, James T.
[J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
[10] Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Gladman, Dafna D.
Rigby, William
Azevedo, Valderilio F.
Behrens, Frank
Blanco, Ricardo
Kaszuba, Andrzej
Kudlacz, Elizabeth
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
Kanik, Keith S.
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68

← 1 2 3 4 5 →